...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Epizyme market cap $750 mil USd
4
Jun 16, 2017 12:38PM

Thinking outside the box, I am wondering if maybe   if a deal is being worked out for a partnership or buyout of Zenith that this in effect will cause a similar deal with RVX soon after , It has been talked about that the competition for acquiring a biotech co in the Epigenetics field  might just heat up,  all just talk but a possibility,  time will tell but things could get interesting in the few months 

 

Share
New Message
Please login to post a reply